A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study.

University of Alabama at Birmingham, 1530 3rd Avenue South, CH-19, Ste-219, Birmingham, AL 35294-2041, USA.
European Heart Journal (Impact Factor: 14.72). 07/2009; 30(16):2029-37. DOI: 10.1093/eurheartj/ehp222
Source: PubMed

ABSTRACT Atrial fibrillation (AF)-associated poor outcomes in heart failure (HF) are often attributed to older age, advanced disease, and comorbidity burden of HF patients with AF. Therefore, we examined the effect of AF on outcomes in a propensity-matched study in which patients with and without AF were well balanced on all measured baseline characteristics.
Of the 2708 advanced chronic systolic HF patients in the Beta-Blocker Evaluation of Survival Trial, 653 had a history of AF. Propensity scores for AF were calculated for each patient and were used to assemble a cohort of 487 pairs of patients with and without AF who were balanced on 74 baseline characteristics. Matched Cox regression analyses were used to estimate associations of AF with outcomes during 23 months of mean follow-up. All-cause mortality occurred in 187 (rate, 2046/10,000 person-years of follow-up) and 181 (rate, 1885/10,000 person-years) matched patients with and without AF, respectively [matched hazard ratio (HR) when AF was compared with no-AF 1.03, 95% confidence interval (CI) 0.79-1.33; P = 0.84]. Heart failure hospitalization occurred in 215 (rate, 3171/10,000 person-years) and 184 (rate, 2405/10,000 person-years) matched patients with and without AF, respectively (matched HR when AF was compared with no-AF 1.28, 95% CI 1.00-1.63; P = 0.049). Hazard ratios and 95% CIs for AF-associated HF hospitalization for bucindolol and placebo groups were, respectively, 1.08 (0.81-1.43) and 1.54 (1.17-2.03; P for interaction = 0.09).
A history of AF had no intrinsic association with mortality but was associated with HF hospitalization in chronic systolic HF.


Available from: Michel White, Mar 28, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: -Characteristics and outcomes of patients with heart failure and reduced ejection fraction (HFrEF) receiving care at Veterans Affairs (VA) vs. non-VA hospitals have not been previously reported. -In the randomized controlled Beta-Blocker Evaluation of Survival Trial (BEST; 1995-1999), of the 2707 (bucindolol=1353; placebo=1354) patients with HFrEF (EF ≤35%), 918 received care at VA hospitals, of which 98% (n=898) were men. Of the 1789 receiving care at non-VA hospitals, 68% (n=1216) were men. Our analyses were restricted to these 2114 male patients. VA patients were older with higher symptom and comorbidity burdens. There was no significant between-group difference in unadjusted primary endpoint of 2-year all-cause mortality (35% VA vs. 32% non-VA; hazard ratio {HR}, 1.09; 95% confidence interval {CI}, 0.94-1.26), which remained unchanged after adjustment for age and race (HR, 1.00; 95% CI, 0.86-1.16) or multivariable-adjustment including cardiovascular morbidities (HR, 0.94; 95% CI, 0.80-1.10). There was no between-group differences in cause-specific mortalities or hospitalizations. Chronic kidney disease, pulmonary edema, left ventricular EF <20% and peripheral arterial disease were significant predictors of mortality for both groups. African America race, New York Heart Association class IV symptoms, atrial fibrillation and right ventricular EF <20% were associated with higher mortality among non-VA hospital patients only; however, these differences from VA patients were not significant. -Patients with HFrEF receiving care at VA hospitals were older and sicker; yet their risk of mortality and hospitalization was similar to those younger and healthier receiving care at non-VA hospitals. Clinical Trial Registration-URL: Unique identifier: NCT00000560.
    Circulation Heart Failure 12/2014; 8(1). DOI:10.1161/CIRCHEARTFAILURE.114.001300 · 5.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: -Little is known about associations of calcium channel blockers (CCBs) with outcomes in patients with heart failure and preserved ejection fraction (HFpEF).
    Circulation Heart Failure 10/2014; DOI:10.1161/CIRCHEARTFAILURE.114.001301 · 5.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Studies on atrial fibrillation (AF) in decompensated heart failure (DHF) are scarce in Brazil. Objectives: To determine AF prevalence, its types and associated factors in patients hospitalized due to DHF; to assess their thromboembolic risk profile and anticoagulation rate; and to assess the impact of AF on in-hospital mortality and hospital length of stay. Methods: Retrospective, observational, cross-sectional study of incident cases including 659 consecutive hospitalizations due to DHF, from 01/01/2006 to 12/31/2011. The thromboembolic risk was assessed by using CHADSVASc score. On univariate analysis, the chi-square, Student t and Mann Whitney tests were used. On multivariate analysis, logistic regression was used. Results: The prevalence of AF was 40%, and the permanent type predominated (73.5%). On multivariate model, AF associated with advanced age (p < 0.0001), non-ischemic etiology (p = 0.02), right ventricular dysfunction (p = 0.03), lower systolic blood pressure (SBP) (p = 0.02), higher ejection fraction (EF) (p < 0.0001) and enlarged left atrium (LA) (p < 0.0001). The median CHADSVASc score was 4, and 90% of the cases had it ≥ 2. The anticoagulation rate was 52.8% on admission and 66.8% on discharge, being lower for higher scores. The group with AF had higher in-hospital mortality (11.0% versus 8.1%, p = 0.21) and longer hospital length of stay (20.5 ± 16 versus 16.3 ± 12, p = 0.001). Conclusions: Atrial fibrillation is frequent in DHF, the most prevalent type being permanent AF. Atrial fibrillation is associated with more advanced age, non-ischemic etiology, right ventricular dysfunction, lower SBP, higher EF and enlarged LA. Despite the high thromboembolic risk profile, anticoagulation is underutilized. The presence of AF is associated with longer hospital length of stay and high mortality.
    Arquivos Brasileiros de Cardiologia 08/2014; DOI:10.5935/abc.20140123 · 1.12 Impact Factor